461 results about "Immune complex deposition" patented technology

The present invention relates to antibodies or fragments thereof that specifically bind the extracellular domain of FcγRIIB, particularly human FcγRIIB, and block the Fc binding site of human FcγRIIB. The invention provides methods of treating cancer and/or regulating immune complex mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, more particularly the extracellular domain of FcγRIIB with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA, and block the Fc binding site of FcγRIIB. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The present invention also encompasses the use of an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in combination with other cancer therapies. The present invention provides pharmaceutical compositions comprising an anti-FcγRIIB antibody or an antigen-binding fragment thereof, in amounts effective to prevent, treat, manage, or ameliorate a cancer, such as a B-cell malignancy, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention further provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention with a vaccine composition. The invention further provides methods of treating cancer and/or regulating immune complex-mediated cell activation by administering the antibodies of the invention to enhance an immune response. The invention also provides methods of breaking tolerance to an antigen by administering an antigen-antibody complex and an antibody of the invention.

The invention is based in part on the finding that suppressing regulatory T cell function is needed in order to convert passive immunity into active antigen-specific immunity. Generally, the methods of the invention comprise at least the combination of: (1) increasing the amount of immune complexes in the subject, wherein the immune complex comprises a target antigen and a immunoglobulin molecule comprising (i) a variable region specific to the target antigen and (ii) a Fc receptor binding region; and (2) inhibiting regulatory T cell function or decreasing/depleting the regulatory T cell population in the subject.

The present invention discloses a quantum point labeled sandwich immunodetection method and its diagnosis kit. It is a new type sandwich immunodetection method using QDs nano particle as label to make antigen antibody specificity sandwich reaction. It includes the following processes: firstly, directly or indirectly enveloping captured antibody in microwell of polystyrene plate, forming captured antibody-antigen-detection antibody three-layer sandwich luminescent immune complex and fluorescence intensity detection. According to that every QD has narrow and symmetrical fluorescence spectral peak it can select and use quantum point label needle sending different light to simultaneously detect several antigens to be tested in same sample.

The invention discloses a new traditional Chinese medicine composition for treating chronic hepatitis and a preparation method thereof. The traditional Chinese medicine composition mainly comprises the following Chinese medicinal herbs of dried orange peel, rhizoma cyperi, pericarpium citri reticulatae viride, radix scrophulariae, root of rehmannia, folium isatidis, root of kudzu vine, houttuynia cordata, indigo naturalis, peach kernel, red flower, radix paeoniae alba, Tuckahoe, rhizoma alismatis, oriental wormwood, desmodium, polygonum cuspidatum, root of red-rooted salvia, radix bupleuri, angelica sinensis, herba lycopi, earthworm, goldthread, felwort and root bark of the peony tree. The traditional Chinese medicine composition can be prepared into a common oral preparation according to a conventional traditional Chinese medicine preparation method. The invention can remarkably improve the symptoms of mild acratia, inappetence, abdominal distension, pain over the liver and the like of chronic persisting hepatitis, and can improve the symptoms of asthenia, poor appetite, abdominal distension, semiliquid, pain over the liver, poor complexion, poorer health, manpower reduction, hepatomegaly accompanied with haphalgesia and rap pain, and splenomegaly of the chronic active hepatitis and the symptoms of jaundice, spider angioma, liver palms, acne and the like caused by the chronic hepatitis. The invention can also improve the symptoms of long-term obvious dysfunction of liver, ALT continuous increase or repeated fluctuation, albumin reduction, globulin increase, gamma globulin or IgG increase, time extension of protrombin time, capability of positive reaction in self antibody and rheumatoid factors, capability of circulating immune complex increase, capability of addiments C3 and C4 reduction and the like, and has accurate remarkable clinical treatment effect and rapid effect taking.

The invention provides an indirect competitive quantum dot fluorescence immunological detection method for synchronously detecting multiple small molecular compounds and detection kit, wherein the immunological detection method is a liquid phase immunological detection method which uses an encoded microsphere as a solid phase carrier and a quantum dot as a fluorescent marker and is used for competitive specificity reactions of a small molecular compound antigen. c Firstly, a captured antigen is covalently bound to the surface of the encoded microsphere, an indirect competitive fluorescent immune complex of microsphere-captured antigen-detected antibody-second antibody-quantum dot is formed in a filter film plate reaction hole through capturing the antigen, detecting the antibody and binding the second antibody specificity, and then the indirect competitive fluorescent immune complex flows across a suspension chip or a detection region of a flow analysis system one by one under the restraint of the sheath fluid, recognizes different encoded microspheres and detects the fluorescent intensity (or average fluorescence intensity) of the quantum dot to complete the detection. A plurality of small molecule compounds in the same sample can be synchronously detected, and one or more small molecule compounds in different samples can also be detected. The invention has the advantages of fast speed and high flux.

A process for preparing a patient-specific immunoadsorber, which comprises (i) extracting a body fluid from a patient having an immunopathological condition, the fluid containing immune complexes that are relevant to that immunopathological condition, (ii) contacting the extracted fluid with an adsorbent for the immune complexes to form adsorbed immune complexes, (iii) eluting the adsorbed complexes to form an eluate, (iv) fractionating the eluate into a plurality of immune complex component fractions, and (v) immobilizing the immune complex components on one or more biologically compatible carriers activated to bond to its surface one or more desired immune complex components.

An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, an HCV adsorption apparatus including said adsorbent, and a adsorbing method for removing HCV are provided. An adsorbent for removing hepatitis C virus which comprises a compound capable of adsorbing hepatitis C virus as immobilized on a water-insoluble carrier, an adsorption apparatus including said adsorbent, and an adsorbing method for removing HCV.

The invention discloses an application of a Raman encoding microsphere and a method for detecting a tumor marker by utilizing the Raman encoding microsphere, wherein the application of the Raman encoding microsphere refers to the application of the Raman encoding microsphere in tumor marker detection. The method for detecting the tumor marker by utilizing the Raman encoding microsphere comprises the following steps: dispersing the Raman encoding microsphere into a phosphoric acid buffer solution and adding a detection antibody for reaction, thus obtaining a nano probe; then utilizing bovine serum albumin to seal a space bit on the surface of the nano probe, thus obtaining a nano prober marked by Raman encoding; adding serum containing a tumor marker into a solid-phase antibody, reacting and adding the nano prober marked by Raman encoding, thus obtaining an immune complex; and after enriching the immune complex through an additionally added magnetic field, performing SERS (surface enhanced Raman scattering) spectrum detection. The Raman encoding microsphere used in the invention has an ultra-strong SERS effect, and can be used for performing quantitative analysis on a polycomponent ultratrace object, and selecting a large number of molecules with different SERS characteristic oscillation as markers to detect various matters to be detected simultaneously.

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgG₁ fused to the framework region of human IgG₁. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.

A quantitative method for performing an automated diagnostic assay, comprising: incubating a capture reagent with a streptavidin-coated medium to form a solid phase complex; washing the solid phase complex to remove excess capture reagent; incubating the solid phase complex with a serum sample to form an immune complex; washing the immune complex to remove any unbound sample; incubating the immune complex with a conjugate to create an immune-conjugate complex; washing the immune-conjugate complex to remove any unbound conjugate; introducing a substrate capable of generating a quantifiable response; and calibrating the response generated from introducing the substrate.

The invention discloses a gastrin-17 enzymatic chemiluminescence immunoassay kit and belongs to the technical field of chemiluminescence immunoassay analysis. The kit comprises an enzyme label liquid, a gastrin-17 standard, gastrin-17 monoclonal antibody-coated immunomagnetic beads, a sample diluent, a chemiluminescent substrate liquid and a washing liquid. The principle of the gastrin-17 enzymatic chemiluminescence immunoassay kit comprises that a gastrin-17 monoclonal antibody is connected to the surface of a magnetic bead so that a solid phase agent is obtained, and through capture of gastrin-17 in a sample and use of an enzyme-labeled anti-gastrin-17 monoclonal antibody, a solid phase-antibody-antigen-enzyme-labeled antibody sandwiched immune complex is formed. Through combination of a chemiluminescence technology and an immunomagnetic bead technology, the prepared kit has the advantages of high sensitivity, good specificity, wide linearity range and good stability and can satisfy clinical requirements on stomach function detection.

A binding partner, especially an antibody fragment that specifically recognizes an antigen-antibody immune complex between anti-THC and THC (tetrahydrocannabinol), is disclosed. The binding partner facilitates a non-competitive homogenous immunoassay for detection of cannabis use. A test kit comprising the binding partner is also described. Preferably the immunoassay is applied for roadside testing of saliva from suspected drivers.

The invention relates to a magnetic particle chemiluminescence immunoassay method for human thyroglobulin antibodies (TGAb) and belongs to the technical field of immunoassay. TG antigens marked by fluorescein isothiocyanate (FITC) and human IgG antibodies marked by alkaline phosphatase are combined to form an antigen-antibody-second enzyme-labeled antibody sandwich immune complex with a sandwich-like structure. Then, magnetic particles connected with FITC antibodies are added, the antigen-antibody complex is connected to the magnetic particles through specific combination of the FITC antibodies and the FITC and directly deposited in an external magnetic field, and the complex formed by immune reaction can be separated from the other non-combined substances without centrifuging. A kit combines chemiluminescence with the magnetic particles to provide a reaction system close to a homogeneous phase. Compared with the prior art, the kit has the advantages of higher sensitivity, wide linear range, quickness and the like; the cost of a product is greatly reduced; and the kit has a broad application prospect on the aspects of clinical examination and the like.

The invention provides an immunoassay based on a carbon nanomaterial (carbon spot), comprising the following steps of: step A, preparing a carbon spot, and marking an immunoreagent antigen or antibody on a surface of the carbon spot so that the carbon spot becomes an immunoreagent-marked carbon spot; step B, mixing the immunoreagent-marked carbon spot, a sample to be tested and a solid phase substance coated by the immunoreagent antigen or antibody to complete immunoreactions, thus forming an immune complex, and separating the immune complex from a free immunoreagent; and step C, adding an oxidant to the immune complex for chemiluminescence detection, and/or directly enabling the immune complex to be subjected to fluorescence detection. According the immunoassay based on the carbon nanomaterial, the chemiluminescence detection and the fluorescence detection can be performed by using the carbon nanomaterial, and the optical stability is good.